To confirm the safety of the Gastrointestinal hormone Ghrelin against chronic kidney disease patients

An interventional single arm study to confirm the safety of the Gastrointestinal hormone Ghrelin against chronic kidney disease patients.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031180354

Enrollment

Registered

2019-03-18

Start date

2015-12-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease Chronic Kidney Disease

Interventions

Drug injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age 20 and up Stage G4 and G5 Chronic Kidney Disease Patient of Keio University Hospital outpatient clinic who have not underwent dialysis BMI lower than 25 Who have agreed to cooperate with this clinical study with an excellent understanding

Exclusion criteria

Exclusion criteria: Who have severe liver dysfunction Who have cancer Who have severe infectious disease Who have mental disorders Who have allergy against wheat, eggs and milk Women with a possibility of pregnancy Who have been decided to be excluded by the primary doctor

Design outcomes

Primary

Measure	Time frame
Time course of the blood concentration of Ghrelin	—

Secondary

Measure	Time frame
Percentage of the appearance of the side effects of Ghrelin	—

Contacts

Public ContactShuu Wakino

School of Medicine Keio University

shuwakino@z8.keio.jp+81-3-5363-3796

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026